BiotechTube
ViQi

ViQi

San Diego, United States· Est.
viqiai.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

ViQi operates at the intersection of AI, imaging, and life sciences, offering a proprietary SaaS platform for creating custom, predictive AI assays. The company's technology addresses bottlenecks in data analysis for cell and tissue imaging, aiming to speed up drug discovery and improve precision medicine. With a focus on compliance, its platform is designated as an FDA Class I Medical Device Data System (MDDS) and is ISO27001 certified. ViQi appears to be a private, platform-focused company serving biopharma clients through a services and software business model.

AI / Machine LearningDrug Discovery

Technology Platform

Proprietary SaaS platform featuring Phenotypically Targeted AI (PTA™) for building custom, predictive image analysis assays. The platform is an FDA Class I MDDS and ISO27001 certified, designed for high-throughput data management and seamless integration into research workflows.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The growing adoption of AI in drug discovery and the bottleneck in analyzing complex imaging data present a significant market opportunity.
ViQi's focus on regulatory compliance and custom solutions positions it to serve pharmaceutical companies needing validated, tailored assays to accelerate R&D and reduce late-stage failures.

Risk Factors

Key risks include intense competition in the AI drug discovery space, the challenge of scaling a custom-assay business model, and dependence on securing ongoing funding as a private company.
Technological execution and demonstrating clear superiority over existing methods are also critical.

Competitive Landscape

ViQi competes in the crowded AI-for-drug-discovery market against both pure-play platform companies (e.g., Recursion, Exscientia) and large tech entrants. Its differentiation lies in its custom, compliance-first approach to AI-powered image analysis, contrasting with companies offering more standardized or therapeutic-pipeline-driven models.

More companies in Digital Health & Biotech SaaS →More companies in United States →